Lack of association of 5 SNPs in the vicinity of the insulin-degrading enzyme (IDE) gene with late-onset Alzheimer's disease

Neuroscience Letters

Volumn 406, Issue 3, 2006, Pages 265-269

  Ozturk, Ayla ^a   DeKosky, Steven T ^b   Kamboh, M Ilyas ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Chromosome 10; Genetics; Polymorphisms

Indexed keywords

INSULINASE;

AGED; ALZHEIMER DISEASE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK; SAMPLING; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALZHEIMER DISEASE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INSULYSIN; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33748194140     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.07.054     Document Type: Article

References (23)

1. Abraham R., Myers A., Wavrant-DeVrieze F., Hamshere M.L., Thomas H.V., Marshall H., Compton D., Spurlock G., Turic D., Hoogendoorn B., Kwon J.M., Petersen R.C., Tangalos E., Norton J., Morris J.C., Bullock R., Liolitsa D., Lovestone S., Hardy J., Goate A., O'Donovan M., Williams J., Owen M.J., and Jones L. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Hum. Genet. 109 (2001) 646-652
2. Bertram L., Blacker D., Mullin K., Keeney D., Jones J., Basu S., Yhu S., McInnis M.G., Go R.C., Vekrellis K., Vekrellis K., Selkoe D.J., Saunders A.J., and Tanzi R.E. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290 (2000) 2302-2303
3. Bian L., Yang J.D., Guo T.W., Sun Y., Duan S.W., Chen W.Y., Pan Y.X., Feng G.Y., and He L. Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese. Neurology 63 (2004) 241-245
4. Blacker D., Bertram L., Saunders A.J., Moscarillo T.J., Albert M.S., Wiener H., Perry R.T., Collins J.S., Harrell L.E., Go R.C., Mahoney A., Beaty T., Fallin M.D., Avramopoulos D., Chase G.A., Folstein M.F., McInnis M.G., Bassett S.S., Doheny K.J., Pugh E.W., and Tanzi R.E. Results of a high resolution genome screen of 437 Alzheimer's disease families. Hum. Mol. Genet. 12 (2003) 23-32
5. Blomqvist M.E., Chalmers K., Andreasen N., Bogdanovic N., Wilcock G.K., Cairns N.J., Feuk L., Brookes A.J., Love S., Blennow K., Kehoe P.G., and Prince J.A. Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain. Neurobiol. Aging 26 (2005) 795-802
6. Boussaha M., Hannequin D., Verpillat P., Brice A., Frebourg T., and Campion D. Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease. Neurosci. Lett. 329 (2002) 121-123
7. Edland S.D., Wavrant-De Vriese F., Compton D., Smith G.E., Ivnik R., Boeve B.F., Tangalos E.G., and Petersen R.D. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE). Neurosci. Lett. 345 (2003) 21-24
8. Ertekin-Taner N., Allen M., Fadale D., Scanlin L., Younkin L., Petersen R.C., Graff-Radford N., and Younkin S.G. Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease. Hum. Mutat. 23 (2004) 334-342
9. Ertekin-Taner N., Graff-Radford N., Younkin L.H., Eckman C., Baker M., Adamson J., Ronald J., Blangero J., Hutton M., and Younkin S.G. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 290 (2000) 2303-2304
10. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., and Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. 100 (2003) 4162-4167
11. Leissring M.A., Farris W., Wu X., Christodoulou D.C., Haigis M.C., Guarente L., and Selkoe D.J. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40 (2003) 1087-1093
12. Lewontin R.C. The interaction of selection and linkage. ii. Optimum models. Genetics 50 (1964) 757-782
13. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
14. Miller B.C., Eckman E.A., Sambamurti K., Dobbs N., Chow K.M., Eckman C.B., Hersh L.B., and Thiele D.L. Amyloid-beta peptide levels in brain are inversely correlated with insulin activity levels in vivo. Proc. Natl. Acad. Sci. 100 (2003) 6221-6226
15. Mukherjee A., Song E., Kihiko-Ehmann M., Goodman J.P., Pyrek J.S., Estus S., and Hersh L.B. Insulin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J. Neurosci. 20 (2000) 8745-8749
16. Myers A., Holmans P., Marshall H., Kwon J., Meyer D., Ramic D., Shears S., Booth J., DeVrieze F.W., Crook R., Hamshere M., Abraham R., Tunstall N., Rice F., Carty S., Lillystone S., Kehoe P., Rudrasingham V., Jones L., Lovestone S., Perez-Tur J., Williams J., Owen M.J., Hardy J., and Goate A.M. Susceptibility locus for Alzheimer's disease on chromosome 10. Science 290 (2000) 2304-2305
17. Myers A., Wavrant De-Vrieze F., Holmans P., Hamshere M., Crook R., Compton D., Marshall H., Meyer D., Shears S., Booth J., Ramic D., Knowles H., Morris J.C., Williams N., Norton N., Abraham R., Kehoe P., Williams H., Rudrasingham V., Rice F., Giles P., Tunstall N., Jones L., Lovestone S., Williams J., Owen M.J., Hardy J., and Goate A. Full genome screen for Alzheimer disease: stage II analysis. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 114 (2002) 235-244
18. Nowotny P., Hinrichs A.L., Smemo S., Kauwe J.S., Maxwell T., Holmans P., Hamshere M., Turic D., Jehu L., Hollingworth P., Moore P., Bryden L., Myers A., Doil L.M., Tacey K.M., Gibson A.M., McKeith I.G., Perry R.H., Morris C.M., Thal L., Morris J.C., O'Donovan M.C., Lovestone S., Grupe A., Hardy J., Owen M.J., Williams J., and Goate A. Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 136 (2005) 62-68
19. Prince J.A., Feuk L., Gu H.F., Johansson B., Gatz M., Blennow K., and Brookes A.J. Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum. Mutat. 22 (2003) 363-371
20. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., and Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J. Biol. Chem. 273 (1998) 32730-32738
21. Sakai A., Ujike H., Nakata K., Takehisa Y., Imamura T., Uchida N., Kanzaki A., Yamamoto M., Fujisawa Y., Okumura K., and Kuroda S. No association between the insulin degrading enzymegene and Alzheimer's disease in a Japanese population. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 125 (2004) 87-91
22. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., and Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2 (1996) 864-870
23. Wang X., DeKosky S., Luedecking-Zimmer E., Ganguli M., and Kamboh M.I. Genetic variation in alpha-1 antichymotrypsin and its association with Alzheimer's disease. Hum. Genet. 110 (2002) 6-65